148528-72-7

Upstream product

• 2448-45-5 Cbz-D-Phe 
• 325789-41-1 tert-butyl [(R)-1-(3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-carbamate 
• 41518-17-6 C₂₂H₂₅NO₆ 
• 107-85-7 1-amino-3-methylbutane 
• 148528-71-6 N-carbobenzyloxy-D-phenylalanine isopentylamide 

Downstream Products

• 1032767-70-6 tert-butyl (S)-6-tert-butoxycarbonylamino-2-{3-[(R)-1-(3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-ureido}-hexanoate 

Relevant academic research and scientific papers

UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa

The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

N-Haloacetyl-amino-acid amides as active-site-directed inhibitors of papain and cathepsin B

A series of N-haloacetyl-amino-acid amides were synthesized and tested as models of cysteine-protease inhibitors. They irreversibly inactivated papain and cathepsin B via a reversible enzyme-inhibitor intermediate. Apparent second-order rate constants of inactivation ranging from 65 to 16,700 M-1 s-1 were observed. Reactivity against papain, as compared to glutathione, was increased 16,400-fold for N-bromoacetyl-leucine isopentylamide and 25,700-fold for the corresponding iodoacetyl derivative; these increases are probably due to proximity effects. No inhibition of trypsin, chymotrypsin and porcine pancreatic elastase was observed. Haloacetamides represent an interesting class of easily synthesized, efficient, irreversible inhibitors of cysteine proteases, which have low non-specific alkylating properties.